Skip to content


Cellular & Molecular Biology Letters

Open Access

Molecular cloning and characterization of a novel anti-TLR9 intrabody

  • Elisa Reimer198,
  • Stefan Somplatzki198,
  • Diana Zegenhagen198,
  • Svenja Hänel198,
  • Alina Fels198,
  • Thorsten Bollhorst198,
  • Ludger Grosse Hovest298,
  • Stefan Bauer398,
  • Carsten J. Kirschning498 and
  • Thomas Böldicke198Email author
Cellular & Molecular Biology LettersAn International Journal201318:98

Received: 4 February 2013

Accepted: 16 July 2013

Published: 26 July 2013


Toll-like receptor 9 (TLR9) is a component of the innate immune system, which recognizes the DNA of both pathogens and hosts. Thus, it can drive autoimmune diseases. Intracellular antibodies expressed inside the ER block transitory protein functions by inhibiting the translocation of the protein from the ER to its subcellular destination. Here, we describe the construction and characterization of an anti-TLR9 ER intrabody (αT9ib). The respective single-chain Fv comprises the variable domains of the heavy and light chain of a monoclonal antibody (mAb; 5G5) towards human and murine TLR9. Co-expression of αT9ib and mouse TLR9 in HEK293 cells resulted in co-localization of both molecules with the ER marker calnexin. Co-immunoprecipitation of mouse TLR9 with αT9ib indicated that αT9ib interacts with its cognate antigen. The expression of αT9ib inhibited NF-κB-driven reporter gene activation upon CpG DNA challenge but not the activation of TLR3 or TLR4. Consequently, TLR9-driven TNFα production was inhibited in RAW264.7 macrophages upon transfection with the αT9ib expression plasmid. The αT9ib-encoding open reading frame was integrated into an adenoviral cosmid vector to produce the recombinant adenovirus (AdV)-αT9ib. Transduction with AdVαT9ib specifically inhibited TLR9-driven cellular TNFα release. These data strongly indicate that αT9ib is a very promising experimental tool to block TLR9 signaling.

Key words

Recombinant antibodiesRecombinant adenovirusProtein knockdownIntracellular toll-like receptorsTLR9ER intrabodiesMacrophage activation